BioTime Expands OpRegen® Clinical Trial in Dry-AMD With Opening of First US Sites
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE MKT:BTX), a clinical-stage biotechnology company developing and commercializing products addressing degenerative diseases, today announced the expansion of its ongoing Phase I/IIa clinical trial for OpRegen® in the advanced dry form age-related macular degeneration (dry-AMD) by naming the first two sites that will treat patients in the U.S. “The addition of U.S. clinical trial sites is an important step in the acceleration of our clinical de